

THE IMPACT OF PREFORMED DONOR SPECIFIC ANTIBODIES (DSA) ON OUTCOMES OF SIMULTANEOUS LIVER KIDNEY (SLK) TRANSPLANT RECIPIENTS



MAYO CLINIC ARIZONA

H. Khamash , C. Jadowiec , B. Lizaola-Mayo , P. Budhiraja , S. Alasfar , H. Me ,
B. G. Abu Jawdeh , K. Reddy , A. Jaramillo , R. Heilman , B. Aqel , A. K. Mathur

TTS 2024 Istanbul

BACKGROUND/OBJECTIVES

- Simultaneous liver kidney transplant recipients have excellent outcomes in terms of rejection rates due to the tolerizing effect of the liver transplant.
- It is mandatory to obtain a crossmatch prior to SLK transplant but not uncommonly a transplant will proceed with only a virtual crossmatch.
- **Aim:** Assess the impact of preformed DSAs on outcomes.

METHODS

- This is a retrospective single center study of all SLK recipients from January 2017 to December 2022.
- 122 patients were included in this study.
- 13 patients were excluded due to primary organ non function or death within 1 month. No cases with rejection were excluded.
- We do not exclude donor HLA antigens regardless of recipient sensitization.
- HLA antibody data was reviewed at time of transplant and on follow up.
- Variables including graft and patient survival, and function were tracked through November 2023.

RESULTS

- 25 patients had DSA and 15 had positive FCXM.
- 16/25 had cPRA > 20% in the DSA group compared to 12/97 in the no-DSA group.
- 9 patients had Class I DSA, 11 Class II DSA, and 5 had both. Mean fluorescence intensity ranged from 1000 - >20000.
- DSAs have resolved on follow up in 12/23 patients and persisted in 11/23, 9 were class II.
- Rejection was more common in the DSA group, 3/6 cases were due to preformed antibodies, rest were cellular rejection in the setting of immunosuppression reduction.
- Antibody mediated rejection AMR cases except for 1 were successfully treated.
- Induction was mostly with basiliximab except for 5 recipients received rATG.
- Maintenance immunosuppression was with tacrolimus, MMF, and prednisone which was tapered off unless DSAs were present.


RESULTS

Table 1

	No-DSA (n=97)	DSA (n=25)	p
Age (yrs)	59±11.2	59.6±9.8	NS
Gender (F)	31 (32%)	9 (36%)	NS
DCD	47 (48.5%)	11 (44%)	NS
KDPI median	38% (19%-51%)	39% (22%-61%)	NS
Delayed function Kidney	37 (38%)	7 (28%)	NS
Rejection Kidney	4 (4.3%)	6 (24%)	0.002
Rejection Liver	6 (6.5%)	4 (16.7%)	NS
Creatinine at follow-up	1.26 ± 0.34	1.25 ± 0.3.2	NS

RESULTS

Deaths Censored Graft Survival



CONCLUSIONS

- Increased risk for rejection in the DSA group did not impact patient and graft survival.
- At our center we do not list unacceptable antigens for SLK candidates.